Analysts’ recommendations and target price
Wall Street analysts expect a potential upside of 32.04% for BioMarin Pharmaceutical (BMRN) based on the stock’s closing price on March 21.
Analysts first revised the company’s target price downward from $120.59 in January to $119.65 in February but then raised it to $119.87 in March. The current consensus analyst recommendation for the stock is a “buy.”
Of the 26 analysts covering BioMarin Pharmaceutical, ten have given it “strong buys,” ten have given it “buys,” and six have given it “holds.” The highest target price estimate for the company is $165, and the lowest is $81.
On March 21, BioMarin Pharmaceutical closed at $90.78, 0.91% higher than its previous closing price, 19.75% higher than its 52-week low of $75.81, and 14.95% lower than its 52-week high of $106.74. The company’s market cap is $16.19 billion.
Based on its closing price on March 21, BioMarin Pharmaceutical has reported returns of -3.94% in the last week, 0.13% in the last month, and 1.34% in the last quarter. The company has reported returns of -8.82% in the last half year, 7.75% in the last year, and 6.61% year-to-date.
In its fourth quarter, BioMarin Pharmaceutical reported revenue of $353.21 million, a YoY (year-over-year) fall of 8.33% and $24.13 million lower than the consensus estimate. The company reported non-GAAP (generally accepted accounting principles) EPS of -$0.06, $0.18 lower than the consensus estimate.
Analysts expect BioMarin Pharmaceutical’s revenue to see YoY rises of 4.94% to $391.89 million in the first quarter, 11.10% to $414.22 million in the second quarter, 11.57% to $437.03 million in the third quarter, and 27.19% to $449.24 million in the fourth quarter of 2019. Analysts also expect BioMarin Pharmaceutical’s revenue to see YoY rises of 13.67% to $1.69 billion in 2019, 15.02% to $1.95 billion in 2020, and 16.09% to $2.26 billion in 2021. According to the company’s fourth-quarter earnings conference call, based on robust uptake in phenylketonuria indications in the US market and the anticipated regulatory approval for this drug in the European market, Palynziq is expected to prove to be the biggest market opportunity to date for the company.
Next, we’ll discuss analysts’ recommendations and projections for United Therapeutics.